OncLive TV

Joshua K. Sabari, MD, discusses response rates observed with zidesamtinib in patients with advanced ROS1-positive non–small cell lung cancer.

Karie Danielle Keera Runcie, MD, discusses treatment challenges after progression on adjuvant therapy and the potential role for zanzalintinib in renal cell carcinoma.

Thomas Powles, MD, discusses results from a Q-TWiST analysis of belzutifan vs everolimus in previously treated advanced renal cell carcinoma.

Marc Machaalani, MD, discusses retrospective findings from a multi-platform analysis evaluating circulating KIM-1 as a biomarker in metastatic RCC.

Linda R. Duska, MD, MPH, discusses PFS2 data with pembrolizumab plus chemoradiotherapy in newly diagnosed, high-risk cervical cancer.

Richard S. Finn, MD, discusses the background of the MORPHEUS-Liver trial of tiragolumab plus atezolizumab and bevacizumab in HCC.

Erika P. Hamilton, MD, highlights the unmet needs regarding treatment for brain metastases in HER2-positive metastatic breast cancer.

Cathy Eng, MD, FACP, FASCO, discusses a real-world study of the effect of KRAS G12C mutations on outcomes in patients with metastatic colorectal cancer.

Premal H. Thaker, MD, MS, discusses data from a study of IMN-001 plus neoadjuvant chemotherapy in newly diagnosed epithelial ovarian cancer.

Alberto Martini, MD, discusses the evolving role of intravesical therapies in patients with high-risk non–muscle-invasive bladder cancer.

Samuel J. Klempner, MD, discusses the safety and efficacy of givastomig plus nivolumab and chemotherapy in metastatic gastric cancers.

Breelyn Wilky, MD, details personalized therapy approaches for the treatment of patients with GIST.

Benjamin A. Weinberg, MD, FACP, discusses the clinical implications of data with BXCL701 plus pembrolizumab in metastatic pancreatic ductal adenocarcinoma.

Jyoti Mayadev, MD, discusses the value of ctDNA as a prognostic biomarker for relapse and survival in patients with locally advanced cervical cancer.

Heather McArthur, MD, discusses monitoring strategies for interstitial lung disease in patients with HER2-positive breast cancer treated with trastuzumab deruxtecan.

Amrita Krishnan, MD, discusses data for elranatamab plus daratumumab and lenalidomide in newly diagnosed, transplant-ineligible multiple myeloma.

Eric K. Singhi, MD, explains the rationale for evaluating lurbinectedin plus atezolizumab as maintenance therapy after chemotherapy in ES-SCLC.

Jade E. Jones, MD, discusses the importance of identifying the most effective first-line treatment regimen for PD-L1–positive TNBC.

Qian (Janie) Qin, MD, discusses efforts to elucidate the optimal use of radium 223 plus enzalutamide in metastatic castration-resistant prostate cancer.

Aaron C. Logan, MD, PhD, discusses the potential use of obe-cel as definitive treatment in adult relapsed/refractory B-ALL.

Justin T. Jordan, MD, MPH, FAAN, discusses treatment challenges and recent progress made with targeted therapies in adult NF1-associated PNs.

R . Lor Randall, MD, FACS, discusses disparities in global access to care for patients with sarcoma.

Manali Kamdar, MD, discusses an analysis of the timing of CRS and ICANS among patients with MCL and other hematologic malignancies treated with liso-cel.

Laura Huppert, MD, discusses ways that the frontline use of T-DXd in HER2-positive metastatic breast cancer may affect later-line treatment decisions.

Tanios S. Bekaii-Saab, MD, discusses current and emerging therapeutic targets for the treatment of patients with biliary tract cancers.

Tahla Munir, MBChB, PhD, discusses the rationale for a MAIC of the phase 3 SEQUOIA and AMPLIFY trials in chronic lymphocytic leukemia.

Elizabeth Lee, MD, discusses the future of Rina-S in FRα-expressing high-grade serous or endometrioid platinum-resistant ovarian cancer.

Jessica Paulus, ScD, discusses using real-world data to add an external control arm to a study of tucatinib plus liposomal doxorubicin in HER2+ breast cancer.

Marina Kremyanskaya, MD, PhD, details the mechanism of action of divesiran for the treatment of patients with polycythemia vera.

Alexey Danilov, MD, PhD, shares essential factors and unanswered questions regarding treatment sequencing in DLBCL.